-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
MannKind Shares Fall After Completing Initial Stage Lung Disease Study
MannKind Shares Fall After Completing Initial Stage Lung Disease Study
MannKind Corporation (NASDAQ:MNKD) has successfully completed a Phase 1 study of clofazimine inhalation suspension (MNKD 101), an inhalation treatment option for nontuberculous mycobacterial (NTM) lung disease.
The Phase I clinical trial is a single- (SAD) and multiple-ascending dose (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of MNKD-101 in healthy volunteers.
In the single-ascending dose (SAD) portion of the study, 24 adults were enrolled in one of three cohorts (n = 8 per cohort) that received a single inhaled dose of 30 mg, 60 mg or 90 mg clofazimine.
During the multiple-ascending dose (MAD) portion of the study, 16 adults were enrolled in one of two cohorts (n = 8 per cohort) that received a daily inhaled dose of 30 mg or 90 mg clofazimine for a seven-day period.
Michael Castagna, Chief Executive Office, commented: "There is a high unmet need to develop medicines that are well tolerated and effective in alleviating symptoms for those living with NTM lung disease. As we continue to expand our orphan lung diseases focus at MannKind, we are encouraged by what we are seeing with inhaled clofazimine and the future potential to help patients."
The company is planning discussions with the U.S. Food and Drug Administration (FDA) regarding results and the ongoing clinical program.
MannKind anticipates to share detailed data readouts in upcoming publications and scientific conferences.
Nontuberculous mycobacteria (NTM) lung disease is a serious infection that is caused by bacteria common in the environment that can lead to a reduction in lung function, cough, fatigue, and quality of life.
Price Action : MannKind shares are trading around down 3 percent at $3.69 on Tuesday at the time of publication.
MannKind Corporation (NASDAQ:MNKD) has successfully completed a Phase 1 study of clofazimine inhalation suspension (MNKD 101), an inhalation treatment option for nontuberculous mycobacterial (NTM) lung disease.
曼肯德公司(納斯達克代碼:MNKD)已經成功地完成了氯法齊明吸入混懸劑(MNKD101)的第一階段研究,這是一種治療非結核分枝桿菌肺部疾病的吸入療法。
The Phase I clinical trial is a single- (SAD) and multiple-ascending dose (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of MNKD-101 in healthy volunteers.
I期臨牀試驗是一項單次(SAD)和多次遞增劑量(MAD)研究,旨在評估MNKD-101在健康志願者中的安全性、耐受性和藥代動力學(PK)。
In the single-ascending dose (SAD) portion of the study, 24 adults were enrolled in one of three cohorts (n = 8 per cohort) that received a single inhaled dose of 30 mg, 60 mg or 90 mg clofazimine.
在這項研究的單次遞增劑量(SAD)部分,24名成年人被納入三個隊列中的一個(每個隊列n=8),接受單次吸入劑量30 mg、60 mg或90 mg的氯法齊明。
During the multiple-ascending dose (MAD) portion of the study, 16 adults were enrolled in one of two cohorts (n = 8 per cohort) that received a daily inhaled dose of 30 mg or 90 mg clofazimine for a seven-day period.
在研究的多重遞增劑量(MAD)部分,16名成年人被納入兩個隊列中的一個(每個隊列8個),每天接受30毫克或90毫克氯法齊明的吸入劑量,為期7天。
Michael Castagna, Chief Executive Office, commented: "There is a high unmet need to develop medicines that are well tolerated and effective in alleviating symptoms for those living with NTM lung disease. As we continue to expand our orphan lung diseases focus at MannKind, we are encouraged by what we are seeing with inhaled clofazimine and the future potential to help patients."
首席執行官邁克爾·卡斯塔尼亞評論説:“人們迫切需要開發耐受性好、能有效緩解NTM肺部疾病患者症狀的藥物。隨着我們在MannKind繼續擴大我們對孤兒肺部疾病的關注,我們對吸入氯法齊明的情況以及未來幫助患者的潛力感到鼓舞。”
The company is planning discussions with the U.S. Food and Drug Administration (FDA) regarding results and the ongoing clinical program.
該公司正計劃與美國食品和藥物管理局(FDA)就結果和正在進行的臨牀計劃進行討論。
MannKind anticipates to share detailed data readouts in upcoming publications and scientific conferences.
MannKind預計將在即將到來的出版物和科學會議上分享詳細的數據讀數。
Nontuberculous mycobacteria (NTM) lung disease is a serious infection that is caused by bacteria common in the environment that can lead to a reduction in lung function, cough, fatigue, and quality of life.
非結核分枝桿菌(NTM)肺部疾病是一種嚴重的感染,由環境中常見的細菌引起,可導致肺功能下降、咳嗽、疲勞和生活質量。
Price Action : MannKind shares are trading around down 3 percent at $3.69 on Tuesday at the time of publication.
價格行動:截至週二,MannKind的股價下跌約3%,至3.69美元。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧